SELLAS Life Sciences Terminates Material Agreement

TL;DR

**SELLAS just terminated a key agreement, watch for details on what it means for their future.**

AI Summary

SELLAS Life Sciences Group, Inc. announced on January 2, 2024, the termination of a material definitive agreement. This termination, while not detailing the specific agreement, indicates a significant change in the company's operational or financial commitments. For investors, this matters because the termination of a material agreement can impact future revenue streams, expenses, or strategic partnerships, potentially affecting the company's stock valuation.

Why It Matters

This termination could signal a shift in strategy, a failed partnership, or a renegotiation, all of which can affect the company's financial health and future prospects.

Risk Assessment

Risk Level: medium — The termination of a material agreement introduces uncertainty regarding the company's future operations and financial performance, warranting a medium risk assessment.

Analyst Insight

Investors should monitor SELLAS Life Sciences Group, Inc. for further announcements regarding the specific nature of the terminated agreement and its potential impact on the company's strategic direction and financial outlook.

Key Players & Entities

• SELLAS Life Sciences Group, Inc. (company) — the registrant filing the 8-K
• January 2, 2024 (date) — date of the earliest event reported

Forward-Looking Statements

• SELLAS Life Sciences Group, Inc. will provide further details on the terminated agreement and its implications in a subsequent filing or announcement. (SELLAS Life Sciences Group, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
• $50,000,000 — me offer and sell up to an aggregate of $50,000,000 of shares of its common stock, par valu
• $10.5 million — , raising net proceeds of approximately $10.5 million. The foregoing description of the Sale

Filing Documents

• tm241849d1_8k.htm (8-K) — 25KB
• 0001104659-24-000958.txt ( ) — 194KB
• sls-20240102.xsd (EX-101.SCH) — 3KB
• sls-20240102_lab.xml (EX-101.LAB) — 33KB
• sls-20240102_pre.xml (EX-101.PRE) — 22KB
• tm241849d1_8k_htm.xml (XML) — 3KB

02. Termination of a Material Definitive Agreement

Item 1.02. Termination of a Material Definitive Agreement On January 2, 2024, SELLAS Life Sciences Group, Inc. (the "Company") and Cantor Fitzgerald & Co. (the "Agent") mutually agreed to terminate the Controlled Equity Offering SM Sales Agreement, dated April 16, 2021 ("Sales Agreement"), pursuant to which the Company could from time to time offer and sell up to an aggregate of $50,000,000 of shares of its common stock, par value $0.0001 per share, subject to any applicable limits when using Form S-3, through the Agent in "at-the-market-offerings" (the "ATM Program"), as defined in Rule 415 under the Securities Act of 1933, as amended. Additionally, effective as of the date of this report, the Company has terminated the prospectus supplement, filed on April 16, 2021, relating to the ATM Program. Prior to termination, the Company issued and sold 1,294,814 shares of its common stock under the Sales Agreement, raising net proceeds of approximately $10.5 million. The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which was filed as Exhibit 10.41 to the Company's Annual Report on Form 10-K (file No. 001-33958) filed with the Securities and Exchange Commission on March 16, 2023 and incorporated herein by reference.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: January 3, 2024 By: /s/ Barbara A. Wood Name: Barbara A. Wood Title: Executive Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR